Pyxis Oncology, Inc. (PYXS)
PYXS Stock Price Chart
Explore Pyxis Oncology, Inc. interactive price chart. Choose custom timeframes to analyze PYXS price movements and trends.
PYXS Company Profile
Discover essential business fundamentals and corporate details for Pyxis Oncology, Inc. (PYXS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2021
Employees
44.00
Website
https://www.pyxisoncology.comCEO
Lara S. Sullivan MBA
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Financial Timeline
Browse a chronological timeline of Pyxis Oncology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.36.
Earnings released on 14 Aug 2025
EPS came in at -$0.30 surpassing the estimated -$0.36 by +16.67%, while revenue for the quarter reached $2.82M .
Earnings released on 15 May 2025
EPS came in at -$0.35 falling short of the estimated -$0.29 by -20.69%.
Earnings released on 18 Mar 2025
EPS came in at -$0.32 surpassing the estimated -$0.33 by +3.03%, while revenue for the quarter reached $3.40M .
Earnings released on 12 Nov 2024
EPS came in at -$0.35 falling short of the estimated -$0.32 by -9.37%.
Earnings released on 14 Aug 2024
EPS came in at -$0.29 surpassing the estimated -$0.33 by +12.12%.
Earnings released on 14 May 2024
EPS came in at -$0.06 surpassing the estimated -$0.27 by +77.78%, while revenue for the quarter reached $16.15M , beating expectations by +291.89%.
Earnings released on 21 Mar 2024
EPS came in at -$0.33 surpassing the estimated -$0.49 by +32.65%, while revenue for the quarter reached $3.42M , beating expectations by +1.91K%.
Earnings released on 7 Nov 2023
EPS came in at -$0.56 surpassing the estimated -$0.57 by +1.75%.
Earnings released on 11 Aug 2023
EPS came in at -$0.41 surpassing the estimated -$0.66 by +37.88%.
Earnings released on 11 May 2023
EPS came in at -$0.54 surpassing the estimated -$0.84 by +35.71%.
Earnings released on 22 Mar 2023
EPS came in at -$1.04 falling short of the estimated -$0.85 by -22.35%.
Earnings released on 1 Nov 2022
EPS came in at -$0.85 falling short of the estimated -$0.76 by -11.84%.
Earnings released on 15 Aug 2022
EPS came in at -$0.79 falling short of the estimated -$0.68 by -16.18%.
Earnings released on 13 May 2022
EPS came in at -$0.97 falling short of the estimated -$0.62 by -56.45%.
Earnings released on 29 Mar 2022
EPS came in at -$1.98 falling short of the estimated -$0.37 by -435.14%.
Earnings released on 15 Nov 2021
EPS came in at -$8.96 falling short of the estimated -$0.51 by -1.66K%.
Earnings released on 8 Oct 2021
EPS came in at -$0.26 .
Earnings released on 31 Mar 2021
EPS came in at -$1.66 .
Earnings released on 31 Dec 2020
EPS came in at -$0.21 .
Earnings released on 30 Sept 2020
EPS came in at -$0.14 .
PYXS Stock Performance
Access detailed PYXS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.